J. Christopher Prue
General Counsel at RANI THERAPEUTICS HOLDINGS, INC.
Profile
J.
Christopher Prue is currently a Senior Director-Regulatory Affairs at Rani Therapeutics Holdings, Inc. He previously held positions as Principal at The Upjohn Co., Incara Pharmaceuticals Corp., and Purdue Pharma LP.
He also served as VP-Regulatory Affairs & Quality Assurance at BioDelivery Sciences International, Inc., Vice President-Regulatory Affairs at AtheroGenics, Inc., Vice President-Regulatory Affairs at Flexion Therapeutics, Inc., and Vice President-Regulatory Affairs at ABIONYX Pharma SA. Prue received his undergraduate degree from Purdue University and his MBA from Western Michigan University.
J. Christopher Prue active positions
| Companies | Position | Start |
|---|---|---|
| RANI THERAPEUTICS HOLDINGS, INC. | General Counsel | 2021-06-30 |
Former positions of J. Christopher Prue
| Companies | Position | End |
|---|---|---|
AtheroGenics, Inc.
 AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | General Counsel | 2009-07-13 |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | General Counsel | - |
| FLEXION THERAPEUTICS, INC. | General Counsel | - |
| The Upjohn Co. | Corporate Officer/Principal | - |
| Incara Pharmaceuticals Corp. | Corporate Officer/Principal | - |
Training of J. Christopher Prue
| Purdue University | Undergraduate Degree |
| Western Michigan University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ABIONYX PHARMA | Health Technology |
| RANI THERAPEUTICS HOLDINGS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
| The Upjohn Co. | Health Technology |
| Incara Pharmaceuticals Corp. | Health Technology |
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
AtheroGenics, Inc.
AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Purdue Pharma LP
 Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
- Stock Market
- Insiders
- J. Christopher Prue